The expanded ATM facility creates a persistent overhang; monitor daily volume and TD Cowen's selling activity for signs of accelerated distribution. With high short interest, any positive pipeline catalyst could trigger a squeeze, but the ATM cap increase suggests management expects to need more cash, likely capping near-term upside.
Price Chart
Executive Summary
Tyra Biosciences has amended its existing at-the-market (ATM) equity offering agreement with TD Cowen, increasing the maximum aggregate offering amount from $150 million to $250 million after fully utilizing the prior $150 million capacity. The filing signals ongoing dilution risk for existing shareholders as the company continues to access the public equity markets for capital, likely to fund its clinical-stage pipeline. With a $1.9B market cap and high short interest (~16.7%), the market may view this expanded ATM capacity as a near-term overhang on the stock.
Key Facts
- Tyra Biosciences has fully utilized its prior $150 million ATM facility and amended the agreement to allow up to $250 million in total common stock sales.
- The amendment was entered into on August 4, 2026, and the last reported sale price on August 3, 2026 was $32.04 per share.
- The company is a clinical-stage biopharmaceutical firm with no disclosed revenue in this filing, relying on equity offerings for capital.
- Short interest is approximately 16.7% of estimated shares outstanding as of mid-July 2026, indicating significant bearish positioning.
Financial Impact
Potential dilution of up to ~$100 million in additional common stock sales beyond the already-exhausted $150 million facility, representing roughly 5-8% of current market cap at the $32.04 reference price.
Risk Factors
- Continued dilution from ATM sales may pressure the stock price.
- Clinical-stage biotech with no revenue; capital needs are uncertain and may require further equity raises.
- High short interest could amplify downside if the ATM is used aggressively.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-333055 |
| Document: 0001193125-26-333055-index-headers.html | 0001193125-26-333055 |
| Document: 0001193125-26-333055-index.html | 0001193125-26-333055 |
| Document: 0001193125-26-333055.txt | 0001193125-26-333055 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | S-3ASR | $25.07 $25.65 | ▲ +2.31% | ▲ +2.21% | $20.50 (−18.21%) |
Sep 9, 2026 23d ago | 8-K | $22.01 $24.35 | ▲ +10.63% | ▲ +11.73% | $20.50 (−6.84%) |
Aug 4, 2026 8w ago | 424B5 | $25.71 $25.30 | ▲ +1.59% | ▲ +1.95% | $20.50 (+20.25%) |
Jun 26, 2026 13w ago | 144 | $32.11 $30.86 | ▲ +3.89% | ▲ +5.28% | $20.50 (+36.14%) |
May 13, 2026 20w ago | 8-K | $36.19 $33.78 | ▼ −6.66% | ▼ −5.50% | $20.50 (−43.34%) |
Apr 20, 2026 23w ago | 3 | $36.69 $35.06 | ▼ −4.44% | ▼ −5.53% | $20.50 (−44.11%) |
Apr 17, 2026 24w ago | DEFA14A | $35.56 $37.59 | ▲ +5.71% | ▲ +5.15% | $20.50 (−42.34%) |
Apr 17, 2026 24w ago | 8-K | $35.56 $37.59 | ▲ +5.71% | ▲ +5.15% | $20.50 (−42.34%) |
Apr 13, 2026 24w ago | 144 | $35.27 $36.69 | ▲ +4.03% | ▲ +2.63% | $20.50 (−41.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access